Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brexit: UK Secures Ferry Space For Medicines To Circumvent Port Delays

Industry Still Waiting For Details Of Booking Arrangements

Executive Summary

New checks due to be imposed when the UK leaves the EU single market and customs union in 2021 are expected to cause widespread disruption to consignments of medicines and other vital goods at the Channel ports. The government says it has secured space on nine new ferry routes in an effort to help keep supplies going.

You may also be interested in...



Covid-19 Vaccine: UK Experts Caution Against Hopes Of ‘Return To Normal’

The Pfizer/BioNTech coronavirus vaccine results are a cause for celebration, but there is still a long way to go. Safety data are still awaited, as is more information on efficacy, and the mass rollout of the vaccine will pose significant practical challenges.

Brexit: Medicine Supplies Face ‘Significant Disruption’ At Ports

As negotiators struggle to reach agreement on the future UK/EU relationship, pharma firms have been warned to expect major hold-ups next year for medicines crossing the Channel. 

COVID-19 Summit Sees Progress On Test-And-Treat, IP Licensing, & Funding Commitments

Announcements at the second Global COVID-19 Summit included a technology licensing agreement for vaccine and diagnostic products developed by the US NIH, a new partnership to boost the use of testing and antiviral treatments in less wealthy countries, and a flurry of new funding pledges from organizations and companies alike.

Topics

UsernamePublicRestriction

Register

PS143102

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel